FANJ
ZYNE

Financial Architects (New Jersey)’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Financial Architects (New Jersey)’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-400
Closed -$2K – 1525
2019
Q1 		$2K Buy
+400
New +$1.95K ﹤0.01% 1344

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Financial Architects (New Jersey)'s ZYNE Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 400 shares — an estimated $2K sold.

Financial Architects (New Jersey) first reported a position in ZYNE in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

  • Financial Architects (New Jersey) reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 400 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $2K.
  • Financial Architects (New Jersey) first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2019 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Zynerba Pharmaceuticals, Inc position peaked at $2K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.